BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19306543)

  • 1. Scaring up patients.
    Ortolon K
    Tex Med; 2008 Aug; 104(8):43-6. PubMed ID: 19306543
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 4. Hereditary breast and ovarian cancer syndrome.
    ACOG Committee on Practice Bulletins
    Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
    Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylactic surgery recommended for BRCA1 carriers.
    Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
    [No Abstract]   [Full Text] [Related]  

  • 9. The need for public education: "Surveillance and risk reduction strategies" for women at risk for carrying BRCA gene mutations.
    Nisker JA
    J Obstet Gynaecol Can; 2007 Jun; 29(6):510-1. PubMed ID: 17568484
    [No Abstract]   [Full Text] [Related]  

  • 10. Taking family history seriously.
    Burke W
    Ann Intern Med; 2005 Sep; 143(5):388-9. PubMed ID: 16144898
    [No Abstract]   [Full Text] [Related]  

  • 11. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.
    Vos J; Otten W; van Asperen C; Jansen A; Menko F; Tibben A
    Psychooncology; 2008 Aug; 17(8):822-30. PubMed ID: 18157792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preconception counseling for the couple at risk preventing the hereditary breast and ovarian cancer syndrome.
    Beller U
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S29-30. PubMed ID: 20975358
    [No Abstract]   [Full Text] [Related]  

  • 13. Preemptive surgery.
    McAuliffe PF; Cance WG
    Surgery; 2006 Jul; 140(1):1-5. PubMed ID: 16857434
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA to regulate direct-to-consumer genetic tests.
    Brower V
    J Natl Cancer Inst; 2010 Nov; 102(21):1610-2, 1617. PubMed ID: 20966430
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCA screening.
    Obstet Gynecol; 2008 May; 111(5):1205-6. PubMed ID: 18448758
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
    James PA; Harris M; Lindeman GJ; Mitchell G
    J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
    [No Abstract]   [Full Text] [Related]  

  • 17. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families.
    Díez O; Gutiérrez-Enríquez S; Ramón y Cajal T; Alonso C; Balmaña J; Llort G
    J Clin Oncol; 2007 Nov; 25(31):5035-6; author reply 5036-8. PubMed ID: 17971607
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic counseling of medullary breast cancer patients.
    Kroupis C; Lianidou E; Goutas N; Vasilaros S; Yannoukakos D; Petersen MB
    Clin Genet; 2004 Apr; 65(4):343-4. PubMed ID: 15025730
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted tailored management of the breast cancer patient at risk for harboring a germline mutation-current trends affecting the selection of patients considering surgical prophylaxis for breast cancer.
    Silva E
    Breast J; 2009; 15 Suppl 1():S76-80. PubMed ID: 19775334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.